FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1995755728> ?p ?o ?g. }

• W1995755728 endingPage "10889" @default.
• W1995755728 startingPage "10883" @default.
• W1995755728 abstract "Transgenic mice expressing IGFBP-5 in the mammary gland exhibit increased cell death and plasmin generation. Because IGFBP-5 has been reported to bind to plasminogen activator inhibitor-1 (PAI-1), we determined the effects of this interaction in HC11 cells. PAI-1 prevented plasmin generation from plasminogen and inhibited cleavage of focal adhesions, expression of caspase 3, and cell death. IGFBP-5 could in turn prevent the effects of PAI-1. IGFBP-5 mutants with reduced affinity for IGF-I (N-term) or deficient in heparin binding (HEP– and C-term E and F) were also effective. This was surprising because IGFBP-5 reportedly interacts with PAI-1 via its heparin-binding domain. Biosensor analysis confirmed that, although wild-type IGFBP-5 and N-term both bound to PAI-1, the C-term E had greatly decreased interaction with PAI-1. This suggests that IGFBP-5 does not antagonize the actions of PAI-1 by a direct molecular interaction. In a cell-free system, using tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA) to activate plasminogen, PAI-1 inhibited plasmin generation induced by both activators, whereas IGFBP-5 prevented the effects of PAI-1 on tPA but not uPA. Furthermore, we noted that IGFBP-5 activated plasminogen to a greater extent than could be explained solely by inhibition of PAI-1, suggesting that IGFBP-5 could directly activate tPA. Indeed, IGFBP-5 and the C-term E and F were all able to enhance the activity of tPA but not uPA. These data demonstrate that IGFBP-5 can enhance the activity of tPA and that this can result in cell death induced by cleavage of focal adhesions. Thus IGFBP-5 can induce cell death by both sequestering IGF-I and enhancing plasmin generation. Transgenic mice expressing IGFBP-5 in the mammary gland exhibit increased cell death and plasmin generation. Because IGFBP-5 has been reported to bind to plasminogen activator inhibitor-1 (PAI-1), we determined the effects of this interaction in HC11 cells. PAI-1 prevented plasmin generation from plasminogen and inhibited cleavage of focal adhesions, expression of caspase 3, and cell death. IGFBP-5 could in turn prevent the effects of PAI-1. IGFBP-5 mutants with reduced affinity for IGF-I (N-term) or deficient in heparin binding (HEP– and C-term E and F) were also effective. This was surprising because IGFBP-5 reportedly interacts with PAI-1 via its heparin-binding domain. Biosensor analysis confirmed that, although wild-type IGFBP-5 and N-term both bound to PAI-1, the C-term E had greatly decreased interaction with PAI-1. This suggests that IGFBP-5 does not antagonize the actions of PAI-1 by a direct molecular interaction. In a cell-free system, using tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA) to activate plasminogen, PAI-1 inhibited plasmin generation induced by both activators, whereas IGFBP-5 prevented the effects of PAI-1 on tPA but not uPA. Furthermore, we noted that IGFBP-5 activated plasminogen to a greater extent than could be explained solely by inhibition of PAI-1, suggesting that IGFBP-5 could directly activate tPA. Indeed, IGFBP-5 and the C-term E and F were all able to enhance the activity of tPA but not uPA. These data demonstrate that IGFBP-5 can enhance the activity of tPA and that this can result in cell death induced by cleavage of focal adhesions. Thus IGFBP-5 can induce cell death by both sequestering IGF-I and enhancing plasmin generation. We have shown previously a large increase in the concentration of IGFBP-5 protein in the milk of rats after 48 h of mammary involution induced by removal of the suckling young, and we propose that this acts to inhibit IGF-I interaction with its receptor on the epithelial cells, resulting in cell death (1Tonner E. Barber M.C. Travers M.T. Logan A. Flint D.J. Endocrinology. 1997; 138: 5101-5107Crossref PubMed Google Scholar). We subsequently showed this to be the case in three independent studies, involving transgenic animals expressing IGFBP-5 in the mammary gland (2Tonner E. Barber M.C. Allan G.J. Beattie J. Webster J. Whitelaw C.B. Flint D.J. Development (Camb.). 2002; 129: 4547-4557Crossref PubMed Google Scholar) as well as exogenous treatment with IGFBP-5 both in vivo (3Allan G.J. Tonner E. Barber M.C. Travers M.T. Shand J.H. Vernon R.G. Kelly P.A. Binart N. Flint D.J. Endocrinology. 2002; 143: 4310-4319Crossref PubMed Scopus (37) Google Scholar) and in vitro (4Marshman E. Green K.A. Flint D.J. White A. Streuli C.H. Westwood M. J. Cell Sci. 2003; 116: 675-682Crossref PubMed Scopus (78) Google Scholar). More recently we have shown that IGFBP-5 mRNA levels are also significantly increased during involution in the mouse mammary gland (5Boutinaud M. Shand J.H. Park M.A. Phillips K. Beattie J. Flint D.J. Allan G.J. J. Mol. Endocrinol. 2004; 33: 195-207Crossref PubMed Scopus (49) Google Scholar). Changes consistent with a role for IGFBP-5 as an inhibitor of IGF-I-mediated cell survival were evident, because phosphorylation of the type I IGF 3The abbreviations used are: IGF, insulin-like growth factor; IGFBP, IGF-binding protein; WT, wild type; tPA, tissue plasminogen activator; uPA, urokinase plasminogen activator; PAI-1, plasminogen activator inhibitor-1; EACA, ϵ-amino caproic acid; DTT, dithiothreitol; pNA, p-nitroanilide; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; DMEM, Dulbecco's modified Eagle's medium; BSA, bovine serum albumin; PBS, phosphate-buffered saline; RP-HPLC, reverse phase-high pressure liquid chromatography; VLL-pNA, H-Val-Leu-Lys-p-nitroanilide; GST, glutathione S-transferase. 3The abbreviations used are: IGF, insulin-like growth factor; IGFBP, IGF-binding protein; WT, wild type; tPA, tissue plasminogen activator; uPA, urokinase plasminogen activator; PAI-1, plasminogen activator inhibitor-1; EACA, ϵ-amino caproic acid; DTT, dithiothreitol; pNA, p-nitroanilide; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; DMEM, Dulbecco's modified Eagle's medium; BSA, bovine serum albumin; PBS, phosphate-buffered saline; RP-HPLC, reverse phase-high pressure liquid chromatography; VLL-pNA, H-Val-Leu-Lys-p-nitroanilide; GST, glutathione S-transferase. receptor and a downstream signaling molecule Akt were both decreased in IGFBP-5 transgenic mice. Furthermore, these mice exhibited decreased concentrations of two pro-survival molecules, Bcl-2 and Bcl-xL, and increased activity of caspase-3. Most intriguingly, these mice also exhibited increased concentrations of plasmin in their mammary glands. The remodeling of the mammary gland, which occurs at the end of lactation, involves an initial phase in which there are dramatic increases in the rates of apoptosis and a second phase involving extracellular proteases, including the plasminogen system and matrix metalloproteinases, which are involved in degrading the extracellular matrix in the later stages of tissue remodeling (6Lund L.R. Romer J. Thomasset N. Solberg H. Pyke C. Bissell M.J. Dano K. Werb Z. Development (Camb.). 1996; 122: 181-193Crossref PubMed Google Scholar). IGFBP-5 has been reported to bind to PAI-1 and therefore to influence IGF-mediated cell responses (7Nam T.J. Busby Jr., W. Clemmons D.R. Endocrinology. 1997; 138: 2972-2978Crossref PubMed Scopus (69) Google Scholar). Recent studies have suggested that the effects of IGFBP-3 and -5 can be both IGF-dependent and IGF-independent and that interactions with particular extracellular matrix components might influence these responses (8Perks C.M. McCaig C. Clarke J.B. Clemmons D.R. Holly J.M. Biochem. Biophys. Res. Commun. 2002; 294: 995-1000Crossref PubMed Scopus (21) Google Scholar, 9Perks C.M. McCaig C. Clarke J.B. Clemmons D.R. Holly J.M. Biochem. Biophys. Res. Commun. 2002; 294: 988-994Crossref PubMed Scopus (28) Google Scholar). These observations led us to consider whether the extremely high concentrations of IGFBP-5 in milk from involuting mammary glands (∼50–100 μg/ml) were present solely to inhibit IGF actions or whether they were also involved in additional and perhaps IGF-independent actions (10Flint D.J. Tonner E. Allan G.J. J. Mammary Gland Biol. Neoplasia. 2000; 5: 65-73Crossref PubMed Scopus (68) Google Scholar). Thus we were interested in examining whether IGFBP-5 is also involved in the regulation of tissue remodeling via a direct influence upon the plasminogen system. We have identified a specific interaction of IGFBP-5 with αs2-casein (11Tonner E. Allan G.J. Flint D.J. J. Endocrinol. 2000; 167: 265-273Crossref PubMed Scopus (35) Google Scholar). This milk protein has also been shown to bind plasminogen and its activator, tPA (12Heegaard C.W. Andreasen P.A. Petersen T.E. Rasmussen L.K. Fibrinolysis Proteolysis. 1997; 11: 29-36Crossref Scopus (13) Google Scholar), and the physical apposition of all of these molecules adds further weight to the hypothesis that IGFBP-5 may directly influence aspects of plasminogen activation. The aims of this study were therefore to determine whether IGFBP-5 and IGFBP-5 mutants that are unable to bind to IGF-I or heparin are able to interact with PAI-1 and influence plasminogen activation. If so, this could provide a mechanism by which IGFBP-5 could coordinate the induction of cell death (by sequestering IGF-I) with the activation of extracellular matrix degradation by generation of the extracellular protease cascades initiated by plasminogen activators. Cell Culture—The mouse mammary epithelial cell line HC11 (a subclone of COMMA-1D cells derived from mid-pregnant mice) (13Danielson K.G. Oborn C.J. Durban E.M. Butel J.S. Medina D. Proc. Natl. Acad. Sci. U. S. A. 1984; 81: 3756-3760Crossref PubMed Scopus (257) Google Scholar) was a kind gift from Dr. Bruce Whitelaw, Roslin Institute, Edinburgh, Scotland, UK, and was cultured as described previously (14Phillips K. Park M.A. Quarrie L.H. Boutinaud M. Lochrie J.D. Flint D.J. Allan G.J. Beattie J. J. Mol. Endocrinol. 2003; 31: 197-208Crossref PubMed Scopus (24) Google Scholar). Bovine insulin (I-6634), epidermal growth factor (E-4127), and uPA were from Sigma. tPA, plasminogen activator inhibitor-1 (PAI-1), and plasminogen were from Calbiochem. PAI-1 was a mutant form (K154T, Q319L, M354I, and N150H), which is virtually unable to be converted to the latent form (half-life = 145 h at 37 °C, pH 7.4) (15Berkenpas M.B. Lawrence D.A. Ginsburg D. EMBO J. 1995; 14: 2969-2977Crossref PubMed Google Scholar). DMEM (phenol red free 31053-028), penicillin/streptomycin (15140-122), l-glutamine (25030-024), and fetal calf serum were from Invitrogen. When cells reached confluence, cultures were washed with serum-free medium and treated with various combinations of plasminogen, PAI-1, and wtIGFBP-5 or mutant IGFBP-5 proteins in serum-free DMEM containing 0.1% BSA. Cells were cultured for a further 24 h, at which time conditioned medium was removed for analysis of plasmin activity. At the end of the culture period, cell monolayers were washed with PBS, fixed with 4% paraformaldehyde, and stained with crystal violet for histological analysis. After photographing the cells, the crystal violet stain was eluted in PBS containing 1% Triton X-100, and absorbance was read at 590 nm. Treatments were performed in duplicate or triplicate. Focal Adhesions—After fixation, cells were incubated with phalloidin and antibodies to vinculin to identify focal adhesions and actin stress fibers, exactly as described previously (16Deugnier M.A. Faraldo M.M. Rousselle P. Thiery J.P. Glukhova M.A. J. Cell Sci. 1999; 112: 1035-1044Crossref PubMed Google Scholar). Cell Death—Caspase-3 activity was measured using a colorimetric assay kit (Sigma, CASP-3-C) according to the manufacturer's instructions. After 24 h of treatment, cells were lysed on ice for 10 min in cell lysis buffer (50 mm HEPES, pH 7.4, 5 mm CHAPS, 5 mm DTT). Lysates were then incubated with 0.2 mm Ac-Asp-Glu-Val-Asp-p-nitroaniline (Ac-DEVD-pNA) in reaction buffer (20 mm HEPES, pH 7.4, 2 mm EDTA, 0.1% CHAPS, 5 mm DTT) at 37 °C, and the absorbance at 405 nm was read at intervals to measure released pNA. Assay of Plasmin Activity—Plasmin activity was measured by incubating conditioned media, from cells cultured in serum-free conditions, in 50 mm Tris-HCl, 0.1% Tween 20, pH 7.4, with 25 μl of the artificial plasmin substrate 6 mm H-Val-Leu-Lys-p-nitroanilide (VLL-pNA) from Bachem (0554101). The absorbance at 405 nm was measured at 15-min intervals for 4 h, and plasmin activity was determined by the rate of change in absorbance. Plasminogen Activator Assays—tPA and uPA activities were measured indirectly by their ability to convert plasminogen to plasmin followed by cleavage of the plasmin substrate VLL-pNA. tPA or uPA was incubated in the presence or absence of PAI-1 and IGFBP-5 in 96-well plates containing 2 μm plasminogen, 10 μl of 6 mm VLL-pNA, and buffer (50 mm Tris-HCl plus 0.1% Tween 20, pH 7.4). Absorbance at 405 nm was measured at 15-min intervals for 3 h. tPA standards (5–200 ng/ml) were used to determine a dose-response curve. After an initial lag phase, the generation of plasmin increased over the first 15–75 min (depending upon the quantity of tPA), and this period was used to quantitatively assess the effects of IGFBP-5 and PAI-1 on the activity of tPA, using the tPA standards as a reference. tPA activity was also measured directly using the Chromozym-tPA assay (Roche Diagnostics) according to the manufacturer's instructions with the tPA substrate N-methylsulfonyl-d-Phe-Gly-Arg-4-nitranilide acetate. tPA (20 ng/ml) was incubated either alone or in the presence of varying concentrations of IGFBP-5. Absorbance readings were monitored at 405 nm for 4 h. Comparison of tPA Activating Activities of IGFBP-5 with Fibrin—Soluble fibrin fragments were prepared from a suspension of fibrin from human plasma (Sigma). 100 mg/ml fibrin suspension was centrifuged at 14,000 × g for 20 min, and the soluble fraction in the supernatant was used. The protein concentration of soluble fibrin was determined by using the Bradford assay. Such soluble fragments of fibrin have been shown to mimic the effect of polymeric fibrin (17Anonick P.K. Gonias S.L. Biochem. J. 1991; 275: 53-59Crossref PubMed Scopus (29) Google Scholar, 18Nieuwenhuizen W. Ann. N. Y. Acad. Sci. 2001; 936: 237-246Crossref PubMed Scopus (46) Google Scholar). tPA (5 ng/ml) was incubated in the absence or presence of soluble fibrin (1–100 mg/ml) or IGFBP-5 and mutants thereof (1–100 mg/ml) in 96-well plates containing 2 μm plasminogen, 10 μl of 6 mm VLL-pNA and buffer (50 mm Tris-HCl plus 0.1% Tween 20, pH 7.4). Absorbance at 405 nm was measured at 15-min intervals for 3 h. The ability of fibrin and IGFBP-5 to enhance the activity of tPA was also investigated in the presence of two inhibitors of fibrin-mediated tPA enhancement. Fibrin activation of tPA involves fibrin fragments containing C-terminal lysine residues, and we thus used a competitive inhibitor EACA, a lysine analogue, and carboxypeptidase-B that enzymatically removes C-terminal lysine residues. tPA (5 ng/ml) was incubated with fibrin or IGFBP-5 (both at 100 mg/ml) in the absence or presence of 50 mm EACA (Sigma) or 10 mg/ml pancreatic carboxypeptidase-B (Sigma) in 96-well plates containing 10 μl of 2 μm plasminogen, 10 μl of 6 mm VLL-pNA and buffer (50 mm Tris-HCl plus 0.1% Tween 20, pH 7.4). Absorbance at 405 nm was measured at 15-min intervals for 4 h. Production of Recombinant Mouse IGFBP-5—Expression of recombinant IGFBP-5 proteins was carried out using conditions identical to those described by Allan et al. (3Allan G.J. Tonner E. Barber M.C. Travers M.T. Shand J.H. Vernon R.G. Kelly P.A. Binart N. Flint D.J. Endocrinology. 2002; 143: 4310-4319Crossref PubMed Scopus (37) Google Scholar). cDNAs for mouse wtIGFBP-5 and various IGFBP-5 mutants minus the signal peptide-encoding sequence were cloned into the pGEX 6P-1 vector (Amersham Biosciences) between BamHI and EcoRI in the multiple cloning site, so that the proteins would have an N-terminal glutathione S-transferase (GST) tag. The mutants used in this study included N-term, a mutant with five mutations in the N-terminal domain (K68N/P69Q/L70Q/L73Q/L74Q) with greatly reduced affinity for IGFs (19Shand J.H. Beattie J. Song H. Phillips K. Kelly S.M. Flint D.J. Allan G.J. J. Biol. Chem. 2003; 278: 17859-17866Abstract Full Text Full Text PDF PubMed Scopus (46) Google Scholar, 20Imai Y. Moralez A. Andag U. Clarke J.B. Busby Jr., W.H. Clemmons D.R. J. Biol. Chem. 2000; 275: 18188-18194Abstract Full Text Full Text PDF PubMed Scopus (101) Google Scholar), and three C-terminal mutants. The C-terminal mutants consisted of HEP–, in which four basic residues in the C terminus were mutated (R201L/K202E/K206Q/R214A (21Song H. Beattie J. Campbell I.W. Allan G.J. J. Mol. Endocrinol. 2000; 24: 43-51Crossref PubMed Scopus (31) Google Scholar) and C-term E (R201A/K202A/K206A/R207A/K208A/K211A/R214A/R216A/K217A/R218A (22Allan G.J. Tonner E. Szymanowska M. Shand J.H. Kelly S.M. Phillips K. Clegg R.A. Gow I.F. Beattie J. Flint D.J. Endocrinology. 2005; 147: 338-349Crossref PubMed Scopus (15) Google Scholar)), and a mutant, C-term F, based upon C-term E but with additional mutations in the central domain of IGFBP-5 (R136A/R137A), which are involved in a second putative heparin-binding domain (23Song H. Shand J.H. Beattie J. Flint D.J. Allan G.J. J. Mol. Endocrinol. 2001; 26: 229-239Crossref PubMed Scopus (18) Google Scholar). Purification of IGFBPs—IGFBPs were purified from glutathione affinity columns after release from GST using the PreScission Protease system (3Allan G.J. Tonner E. Barber M.C. Travers M.T. Shand J.H. Vernon R.G. Kelly P.A. Binart N. Flint D.J. Endocrinology. 2002; 143: 4310-4319Crossref PubMed Scopus (37) Google Scholar). IGFBP-5 proteins were further purified in two ways, either on IGF affinity columns and quantified as described previously (23Song H. Shand J.H. Beattie J. Flint D.J. Allan G.J. J. Mol. Endocrinol. 2001; 26: 229-239Crossref PubMed Scopus (18) Google Scholar) or by RP-HPLC. This involved using a polymeric column (PLRP-S, 300 Å; 8-μm beads; 4.6 mm diameter × 150 mm; Polymer Laboratories Ltd., Church Stretton, UK) equilibrated with a mobile phase of 25% acetonitrile in 0.1% trifluoroacetic acid. 1-ml aliquots of GST-purified protein (∼2 mg of protein) in cleavage buffer were injected onto the column, which was run at 1 ml/min. Isocratic elution at 25% acetonitrile for 5 min was followed by a gradient of 25–55% acetonitrile over the next 60 min. Absorbance of column eluate was monitored at 220 nm, and fractions were assessed for protein purity by SDS-PAGE and by Western immunoblotting with anti-IGFBP-5, as described previously (24Bramani S. Song H. Beattie J. Tonner E. Flint D.J. Allan G.J. J. Mol. Endocrinol. 1999; 23: 117-123Crossref PubMed Scopus (37) Google Scholar), with quantitation of protein by the Bradford assay. Fractions were lyophilized and stored at –70 °C. Proteins were redissolved in Tris-HCl/Tween 20 buffer, pH 7.4, for use. Biosensor Analysis—Biosensor studies were performed on a fully automated BIAcore 3000 instrument under conditions as described previously (19Shand J.H. Beattie J. Song H. Phillips K. Kelly S.M. Flint D.J. Allan G.J. J. Biol. Chem. 2003; 278: 17859-17866Abstract Full Text Full Text PDF PubMed Scopus (46) Google Scholar, 25Beattie J. Phillips K. Shand J.H. Szymanowska M. Flint D.J. Allan G.J. J. Mol. Endocrinol. 2005; 34: 163-175Crossref PubMed Scopus (24) Google Scholar). The human PAI-1 mutant was dissolved at 10 μg/ml in sodium acetate, pH 5.0, and immobilized to the surface of a carboxymethyl (CM-5) biosensor chip using standard amine coupling chemistry, also as described previously (19Shand J.H. Beattie J. Song H. Phillips K. Kelly S.M. Flint D.J. Allan G.J. J. Biol. Chem. 2003; 278: 17859-17866Abstract Full Text Full Text PDF PubMed Scopus (46) Google Scholar). PAI-1 was immobilized to a level of 1000 resonance units, and bovine serum albumin (BSA) was immobilized to a similar level in a control flow cell. Wild type IGFBP-5, C-term E, and N-term were analyzed for binding to PAI-1 surfaces at concentrations of 0, 93, 187, 375, 750, and 1500 nm at a flow rate of 30 μl/min. Association was for 3 min, and dissociation was for 15 min. Binding was analyzed in duplicate for each protein concentration with randomization of injection for each individual analyte with respect to concentration. Biosensor chip surfaces were regenerated with 1 × 15-s pulses of 100 mm HCl, 0.5 m NaCl prior to the next cycle of analyte binding. Data were analyzed as described previously (19Shand J.H. Beattie J. Song H. Phillips K. Kelly S.M. Flint D.J. Allan G.J. J. Biol. Chem. 2003; 278: 17859-17866Abstract Full Text Full Text PDF PubMed Scopus (46) Google Scholar, 25Beattie J. Phillips K. Shand J.H. Szymanowska M. Flint D.J. Allan G.J. J. Mol. Endocrinol. 2005; 34: 163-175Crossref PubMed Scopus (24) Google Scholar). Although the IGFBP-5 proteins purified by glutathione-Sepharose were relatively pure, we did note, in some preparations, the presence of impurities, particularly IGFBP-5 fragments (see Fig. 1). The majority of these fragments was derived from IGFBP-5 as demonstrated by Western immunoblotting using an antiserum to IGFBP-5 (results not shown). We further purified IGFBP-5, either on an IGF affinity column or by RP-HPLC (Fig. 1). These subsequent purifications produced IGFBP-5, and mutants thereof, devoid of fragments. Wild-type, N-term, and C-term E are shown as examples (Fig. 1). Furthermore, the effects of IGFBP-5 described in our studies were not because of artifactual generation of IGFBP-5 polymers during the purification process, because our preparations run as monomeric proteins under native conditions, which are routinely used for Western ligand blotting (results not shown). HC11 cells attached to the substratum via numerous focal adhesions and exhibited actin stress fibers when cultured in serum-free medium in the absence of plasminogen (Fig. 2a). In contrast, in the presence of plasminogen, there was evidence of cleavage of focal adhesions, some cell migration, and increased cell-cell contact before cells died via anoikis within 12–24 h (Fig. 2, b and c). This was accompanied by a 4-fold increase in the activity of caspase 3 in the cells 24 h post-treatment, an effect that was inhibited in a dose-dependent fashion by PAI-1 (results not shown). Fig. 3a shows a confluent monolayer of HC11 cells cultured in serum-free conditions, stained with crystal violet. IGFBP-5, in the absence of plasminogen, showed no intrinsic ability to modify cell attachment or survival (Fig. 3b). Addition of plasminogen, in contrast, resulted in cell migration and ultimately cell death, indicating the conversion of plasminogen to plasmin by plasminogen activator(s) produced by the cells (Fig. 3c). These plasmin(ogen)-induced effects were completely prevented by PAI-1 (Fig. 3d). However, the addition of IGFBP-5 to cultures containing PAI-1 and plasminogen antagonized the effects of PAI-1 and induced cell detachment (Fig. 3e). In contrast, the pGEX-6P1 empty vector control (potentially containing contaminating proteases from the bacterial expression system) failed to influence the actions of PAI-1 (Fig. 3f). Cell death was also assessed quantitatively after solubilization of crystal violet staining (Fig. 3g) and confirmed the visual changes induced in the cells by the various treatments. These effects were because of plasmin generation as confirmed by measuring plasmin activity in the medium (Fig. 4). After 24 h of culture in serum-free medium, in the absence of exogenous plasminogen, there was no evidence of plasmin activity, either in the presence or absence of IGFBP-5. However, if plasminogen was added to the HC11 cultures, plasmin activity was readily detectable in the medium removed at the end of the 24-h culture period. The addition of PAI-1, together with plasminogen, prevented plasmin formation. When IGFBP-5 was added together with PAI-1 and plasminogen, it was able to prevent the effects of PAI-1, resulting in increased plasmin generation. The pGEX-6P1 plasmid (empty vector control) failed to influence plasmin generation, indicating that any trace contamination of bacterial proteins/proteases following glutathione purification had no effect in these assays.FIGURE 4Plasmin concentration in the medium from cells cultured for 24 h in serum-free medium and treated with plasminogen, PAI-1, and IGFBP-5 as in Fig. 3. 25 μl of medium was collected and mixed with 125 μl of Tris-HCl, 0.1% Tween 20, pH 7.4, and 25 μl of 6 mm VLL-pNA. Readings were taken at A405 at 15-min intervals over 4 h. A representative experiment is shown. Addition of plasminogen (squares) led to rapid generation of plasmin. Addition of PAI-1 with plasminogen (circles) completely prevented this. Addition of plasminogen, PAI-1, and IGFBP-5 (triangles) led to increased plasmin generation. Addition of PAI-1 plus proteins from the pGEX-6P1 empty vector control (crosses) failed to generate plasmin. Finally, there was no endogenous generation of plasmin in the absence of exogenous plasminogen, either without or with IGFBP-5 (diamonds; data for these last two treatments were superimposable). This experiment was performed on at least five occasions for each treatment.View Large Image Figure ViewerDownload Hi-res image Download (PPT) A mutant IGFBP-5 that had greatly reduced affinity for IGF-I (N-term) was as effective as wtIGFBP-5 protein in terms of cell remodeling (Fig. 5e). A mutant HEP–, which had a greatly reduced affinity for heparin, showed only a small decrease in potency when compared with wtIGFBP-5 (Fig. 5f). Details of the properties of these mutants have been reported previously (22Allan G.J. Tonner E. Szymanowska M. Shand J.H. Kelly S.M. Phillips K. Clegg R.A. Gow I.F. Beattie J. Flint D.J. Endocrinology. 2005; 147: 338-349Crossref PubMed Scopus (15) Google Scholar, 23Song H. Shand J.H. Beattie J. Flint D.J. Allan G.J. J. Mol. Endocrinol. 2001; 26: 229-239Crossref PubMed Scopus (18) Google Scholar). Similar observations were made for the C-term E and C-term F, two additional non-heparin-binding mutants (results not shown). These findings were supported by determination of the plasmin concentration in the medium 24 h after addition of the treatments in serum-free medium that paralleled the phenotypic changes (results not shown). These observations indicated that the effect of IGFBP-5 on PAI-1 action was almost entirely unrelated to its ability to bind to IGFs or heparin. Biosensor analysis demonstrated that wtIGFBP-5 bound to PAI-1 with a Kd of ∼100 nm (Fig. 6a). However, the non-heparin-binding mutant C-term E had a greatly reduced affinity for PAI-1 (Fig. 6b), whereas the N-term mutant had a similar affinity to wtIGFBP-5 (Fig. 6c). Given that the C-term E had little affinity for PAI-1, it seemed unlikely that it could antagonize the effects of PAI-1 by a direct molecular interaction. We therefore examined these effects of IGFBP-5 on tPA, uPA, and PAI-1 activities in greater detail by using cell-free studies. As shown in Fig. 7, tPA and uPA generated plasmin from exogenous plasminogen, and PAI-1 could inhibit this in a dose-dependent manner. When IGFBP-5 was added into the tPA/PAI-1 mixture, as anticipated, it markedly inhibited the effect of PAI-1 (Fig. 7A). However, we also noted that, at a lower dose of PAI-1, IGFBP-5 not only inhibited the effect of PAI-1 but actually increased plasmin production to levels even greater than with tPA alone (Fig. 7B). Furthermore, when IGFBP-5 was incubated with uPA plus PAI-1, IGFBP-5 failed to inhibit the action of PAI-1 (Fig. 7C). These results suggested that IGFBP-5 was acting not by inhibiting PAI-1 but by specifically enhancing the activity of tPA but not uPA.FIGURE 6Biosensor analysis of interactions of PAI-1 with IGFBP-5. Individual sensorgrams for wtIGFBP-5 (a), C-term E (b), and N-term (c) binding to the human PAI-1 ligand, which was covalently captured, by amine coupling chemistry to the carboxymethyl surface of a CM5 biosensor chip. RU = resonance units.View Large Image Figure ViewerDownload Hi-res image Download (PPT)FIGURE 7Effects of IGFBP-5 and PAI-1 on tPA- or uPA-mediated plasminogen activation. A, 20 ng/ml tPA was incubated alone (squares), in the presence of 100 ng/ml PAI-1 (triangles), or PAI-1 plus 25 μg/ml IGFBP-5 (circles) with 10 μl of 6 mm VLL-pNA and 2 μm plasminogen in Tris-HCl buffer, pH 7.4, containing 0.1% Tween 20. B, same as in A except that PAI-1 concentration was 25 ng/ml. Note that plasmin activity was greater in the presence of tPA, PAI-1, and IGFBP-5 than in the presence of tPA alone. C, 11 ng/ml uPA was incubated alone (squares), in the presence of 100 ng/ml PAI-1 (triangles), or PAI-1 plus 25 μg/ml IGFBP-5 (circles), with 10 μl of 6 mm VLL-pNA and 2 μm plasminogen in Tris-HCl buffer, pH 7.4, containing 0.1% Tween 20. Absorbance at 405 nm was measured at 15-min intervals for 3 h. Results are means of triplicate wells and are representative of results obtained on three occasions.View Large Image Figure ViewerDownload Hi-res image Download (PPT) We therefore tested the effect of IGFBP-5 on uPA or tPA in the absence of PAI-1. This confirmed our hypothesis, because IGFBP-5 enhanced the effect of tPA on plasminogen in a dose-dependent fashion (Fig. 8A). BSA was used as a control and showed no ability to enhance tPA (Fig. 8B) or uPA activity. In complete contrast, plasmin generation by uPA was not enhanced by IGFBP-5 (Fig. 8C). More importantly, we demonstrated that, in the absence of tPA or uPA, IGFBP-5 possessed no enzymatic activity capable of cleaving plasminogen to plasmin (Fig. 8C). The ability of IGFBP-5 to enhance tPA activity was similar in preparations that were derived from the glutathione column (containing some fragments) as well as the highly purified preparations from HPLC or IGF affinity purifications that were devoid of IGFBP-5 fragments, suggesting that proteolytic fragments of IGFBP-5 present in the bacterially expressed proteins, potentially containing C-terminal lysines, were not major contributors to this effect of IGFBP-5 (results not shown). To examine the possibility that such C-terminal lysines were produced during the incubation with plasminogen, we used EACA, a lysine analogue, and carboxypeptidase-B to inhibit interactions of tPA and plasminogen with the C-terminal lysine residues, potentially present in breakdown products of IGFBP-5. Fibrin was used as a positive control and was able to enhance the activity of tPA in a dose-response fashion, resulting in increases of tPA activity greater than 40-fold (Fig. 9A). IGFBP-5 (Fig. 9C) and C-term E (results not shown) were as potent as soluble fibrin in enhancing tPA activity. EACA inhibited the effects of fibrin in a dose-dependent manner, with 100 mm EACA being completely inhibitory (Fig. 9A). Carboxypeptidase-B also markedly attenuated fibrin-mediated enhancement of tPA (Fig. 9B), and similar effects were evident when IGFBP-5 replaced fibrin (Fig. 9C). We finally determined whether the enhancement of tPA-mediated plasminogen activation by IGFBP-5 was exerted through an induced conformational change in tPA, which enhanced its direct catalytic activity. To examine this, the effect of IGFBP-5 on tPA activity was investigated in a direct amidolytic assay for tPA. IGFBP-5 showed a dose-dependent ability to increase the activity of tPA, although this was more modest (2-fold) than the effect achieved in the indirect assay (results not shown).FIGURE 9Influence of EACA and carboxypeptidase-B on tPA-catalyzed plasminogen cleavage. A, 5 ng/ml tPA was incubated alone (diamonds), with 100 mg/ml fibrin (squares), or with fibrin plus EACA at concentrations of 1 (circles), 10 (triangles), or 100 mm (crosses). B, 5 ng/ml tPA was incubated alone (diamonds), with 100 mg/ml fibrin (squares), or with fibrin plus 50 mm EACA (triangles) or with fibrin plus 10 mg/ml carboxypeptidase B (circles). C, same as for B except that 100 mg/ml IGFBP-5 replaced fibrin. All wells contained 10 μl of 6 mm VLL-pNA and 2 μm plasminogen in Tris-HCl buffer, pH 7.4, containing 0.1% Tween. Absorbance at 405 nm was measured at 15-min intervals for 3 h.View Large Image Figure ViewerDownload Hi-res image Download (PPT) By utilizing the epithelial cell line HC11, we were able to show that plasmin generation induced proteolytic cleavage of focal adhesions and disruption of actin stress fibers, which ultimately led to cell death as indicated by activation of caspase-3 and eventual cell detachment. These effects were inhibited by PAI-1, and we now show for the first time that IGFBP-5 can prevent these effects of PAI-1. This clearly suggests that the physical interaction of IGFBP-5 with PAI-1, as described previously (7Nam T.J. Busby Jr., W. Clemmons D.R. Endocrinology. 1997; 138: 2972-2978Crossref PubMed Scopus (69) Google Scholar), serves to inhibit the actions of PAI-1. Subsequently, we showed that IGFBP-5 mutants that were unable to bind either to IGF-I or heparin were also able to antagonize the effects of PAI-1. This was somewhat surprising given that PAI-1 has been described to interact with IGFBP-5 via its heparin-binding domain (amino acids 201–218). We thus examined IGFBP-5 interactions with PAI-1 using biosensor analysis and showed that IGFBP-5 did indeed bind to PAI-1, whereas a heparin-binding mutant (C-term E) used in this study showed greatly compromised binding to PAI-1, supporting the earlier findings of Clemmons and co-workers (7Nam T.J. Busby Jr., W. Clemmons D.R. Endocrinology. 1997; 138: 2972-2978Crossref PubMed Scopus (69) Google Scholar). It was thus puzzling that a mutant with limited ability to bind to PAI-1 could nevertheless prevent the effects of PAI-1 on plasmin generation. However, we were able to show that IGFBP-5 activated plasminogen independently of PAI-1 by specifically enhancing the activity of tPA directly, although it was unable to influence the effects of uPA and had no intrinsic plasminogen cleaving activity. This finding implies that the interaction of IGFBP-5 with tPA lies out with the basic residues of the heparin-binding domain of IGFBP-5 and presumably out with the major IGF-binding site present in the N terminus of IGFBP-5, because C-term E and N-term were able to enhance tPA activity to a similar extent as wild-type IGFBP-5. The manner in which IGFBP-5 enhanced tPA activity is similar to that of fibrin. The intrinsic activity of tPA against plasminogen is very low but is considerably enhanced by fibrin (26Fischer B. Biol. Chem. Hoppe-Seyler. 1990; 371: 1067-1075Crossref PubMed Scopus (5) Google Scholar). This involves two mechanisms. In the first, fibrin creates a ternary complex with tPA and plasminogen, involving interactions of tPA and plasminogen with C-terminal lysine residues of fibrin, thereby retaining the molecules in close apposition. This mechanism was also evident for IGFBP-5 because the lysine analogue EACA and carboxypeptidase-B inhibited the actions of both IGFBP-5 and fibrin. Carboxypeptidase-B or thrombin-activable fibrinolysis inhibitor inhibits fibrinolysis by removing the C-terminal lysine residues from fibrin that are required for efficient plasmin formation (27Bajzar L. Manuel R. Nesheim M.E. J. Biol. Chem. 1995; 270: 14477-14484Abstract Full Text Full Text PDF PubMed Scopus (649) Google Scholar, 28Bajzar L. Morser J. Nesheim M. J. Biol. Chem. 1996; 271: 16603-16608Abstract Full Text Full Text PDF PubMed Scopus (587) Google Scholar). The second mechanism involves binding of fibrin, or fragments thereof, to tPA, which induces favorable conformational changes in both tPA and plasminogen (29Fischer B.E. Blood Coagul. Fibrinolysis. 1992; 3: 197-204PubMed Google Scholar). IGFBP-5 was also able to act in this way, and this role of IGFBP-5 thus contrasts with that of a-s2 casein, which enhances the activation of tPA exclusively by ternary complex formation and exhibits no ability to enhance tPA activity in the direct amidolytic assay (12Heegaard C.W. Andreasen P.A. Petersen T.E. Rasmussen L.K. Fibrinolysis Proteolysis. 1997; 11: 29-36Crossref Scopus (13) Google Scholar). Most intriguingly, we have shown that IGFBP-5 binds to casein micelles and interacts exclusively with a-s2 casein on ligand blots (11Tonner E. Allan G.J. Flint D.J. J. Endocrinol. 2000; 167: 265-273Crossref PubMed Scopus (35) Google Scholar). It has been proposed that casein micelles thus provide a matrix for plasmin generation in milk and that this serves to prevent formation of casein (milk) clotting. The presence of IGFBP-5 at high concentrations in these matrices, coupled with its ability to bind to PAI-1, provides additional support for a physiological role of IGFBP-5 in the process of plasminogen activation in vivo, at least in the mammary gland. The processes of clotting of milk and blood share numerous features on a molecular and hydrodynamic level (30Christy J.R. Macleod N. Cardiovasc. Res. 1989; 23: 949-959Crossref PubMed Scopus (17) Google Scholar). The fact that IGFBP-5 can serve as an activator of tPA (an important fibrinolytic agent) and the fact that IGFBP-5 is also expressed in situations where atherosclerotic plaques are evident (31Zheng B. Duan C. Clemmons D.R. J. Biol. Chem. 1998; 273: 8994-9000Abstract Full Text Full Text PDF PubMed Scopus (43) Google Scholar, 32Jones J.I. Doerr M.E. Clemmons D.R. Prog. Growth Factor Res. 1995; 6: 319-327Abstract Full Text PDF PubMed Scopus (69) Google Scholar) and that it binds to thrombospondin and osteopontin (33Nam T.J. Busby Jr., W.H. Rees C. Clemmons D.R. Endocrinology. 2000; 141: 1100-1106Crossref PubMed Scopus (94) Google Scholar), which are involved in this process, suggest that IGFBP-5 may, in addition, play an important role in processes such as thrombolysis and wound healing. The possibility that it plays a role in localized inhibition of blood clotting is worthy of investigation. Although IGFBP-5 may play a role in maintaining the patency of mammary milk ducts, the plasminogen activator content of the rodent mammary gland is also correlated with involutionary processes, and thus plasminogen activation is also considered to be involved in the later stages of tissue remodeling (34Ossowski L. Biegel D. Reich E. Cell. 1979; 16: 929-940Abstract Full Text PDF PubMed Scopus (347) Google Scholar). For example, in rodents, an increase in plasminogen activator production and a decrease in PAI-1 activity are correlated with the destruction of the basement membrane and loss of the secretory cells during mammary gland involution (34Ossowski L. Biegel D. Reich E. Cell. 1979; 16: 929-940Abstract Full Text PDF PubMed Scopus (347) Google Scholar, 35Talhouk R.S. Bissell M.J. Werb Z. J. Cell Biol. 1992; 118: 1271-1282Crossref PubMed Scopus (400) Google Scholar, 36Busso N. Huarte J. Vassalli J.D. Sappino A.P. Belin D. J. Biol. Chem. 1989; 264: 7455-7457Abstract Full Text PDF PubMed Google Scholar). Thus IGFBP-5 potentially plays a dual role in mammary gland remodeling during the involutionary process. First, it sequesters IGF-I and induces cell death; and second, it activates tPA and thereby induces the proteolytic cascades, including activation of matrix metalloproteinases, which are involved in degradation of the extracellular matrix in the mammary gland. It is thus likely that IGFBP-5 serves to coordinate these events. In summary, despite the fact that we were able to confirm by biosensor analysis that IGFBP-5 binds to PAI-1, we were unable to show any direct effect of IGFBP-5 on PAI-1 activity. Rather, the ability of IGFBP-5 to counteract the effects of PAI-1 appeared to be indirect, due to activation of tPA but not uPA. Of course, this does not rule out the possibility that IGFBP-5 can influence other actions of PAI-1, such as its ability to modulate cell migration, involving a plasmin-independent process (20Imai Y. Moralez A. Andag U. Clarke J.B. Busby Jr., W.H. Clemmons D.R. J. Biol. Chem. 2000; 275: 18188-18194Abstract Full Text Full Text PDF PubMed Scopus (101) Google Scholar, 37Andreasen P.A. Egelund R. Petersen H.H. Cell. Mol. Life Sci. 2000; 57: 25-40Crossref PubMed Scopus (829) Google Scholar). We thank M. Gardner for skilled technical assistance. We also acknowledge valuable contributions from P. Chiew, P. Deng, H. S. Jing, S. W. Lim, and Y. T. Lim, all students of Ngee Ann Polytechnic, Singapore." @default.
• W1995755728 created "2016-06-24" @default.
• W1995755728 creator A5002685218 @default.
• W1995755728 creator A5005974685 @default.
• W1995755728 creator A5037868315 @default.
• W1995755728 creator A5041806038 @default.
• W1995755728 creator A5049130253 @default.
• W1995755728 creator A5062796761 @default.
• W1995755728 creator A5066082558 @default.
• W1995755728 creator A5073359098 @default.
• W1995755728 date "2006-04-01" @default.
• W1995755728 modified "2023-10-18" @default.
• W1995755728 title "Insulin-like Growth Factor-binding Protein-5 Activates Plasminogen by Interaction with Tissue Plasminogen Activator, Independently of Its Ability to Bind to Plasminogen Activator Inhibitor-1, Insulin-like Growth Factor-I, or Heparin" @default.
• W1995755728 cites W127801142 @default.
• W1995755728 cites W1603094039 @default.
• W1995755728 cites W167942448 @default.
• W1995755728 cites W175798264 @default.
• W1995755728 cites W1834589661 @default.
• W1995755728 cites W1968262678 @default.
• W1995755728 cites W1974668166 @default.
• W1995755728 cites W1976700349 @default.
• W1995755728 cites W1977497608 @default.
• W1995755728 cites W1983284888 @default.
• W1995755728 cites W1983542670 @default.
• W1995755728 cites W1992221874 @default.
• W1995755728 cites W2013893652 @default.
• W1995755728 cites W2024642928 @default.
• W1995755728 cites W2031310019 @default.
• W1995755728 cites W2039537001 @default.
• W1995755728 cites W2045015715 @default.
• W1995755728 cites W2048106517 @default.
• W1995755728 cites W2063981235 @default.
• W1995755728 cites W2065423329 @default.
• W1995755728 cites W2066822578 @default.
• W1995755728 cites W2071306987 @default.
• W1995755728 cites W2075444548 @default.
• W1995755728 cites W2079195379 @default.
• W1995755728 cites W2095847870 @default.
• W1995755728 cites W2097568177 @default.
• W1995755728 cites W2111144663 @default.
• W1995755728 cites W2116601861 @default.
• W1995755728 cites W2120622189 @default.
• W1995755728 cites W2122935853 @default.
• W1995755728 cites W2128402256 @default.
• W1995755728 cites W2137808717 @default.
• W1995755728 cites W2157639904 @default.
• W1995755728 cites W2159110682 @default.
• W1995755728 cites W2182663022 @default.
• W1995755728 cites W2315266186 @default.
• W1995755728 doi "https://doi.org/10.1074/jbc.m508505200" @default.
• W1995755728 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16505491" @default.
• W1995755728 hasPublicationYear "2006" @default.
• W1995755728 type Work @default.
• W1995755728 sameAs 1995755728 @default.
• W1995755728 citedByCount "33" @default.
• W1995755728 countsByYear W19957557282012 @default.
• W1995755728 countsByYear W19957557282013 @default.
• W1995755728 countsByYear W19957557282015 @default.
• W1995755728 countsByYear W19957557282018 @default.
• W1995755728 countsByYear W19957557282019 @default.
• W1995755728 countsByYear W19957557282020 @default.
• W1995755728 countsByYear W19957557282021 @default.
• W1995755728 crossrefType "journal-article" @default.
• W1995755728 hasAuthorship W1995755728A5002685218 @default.
• W1995755728 hasAuthorship W1995755728A5005974685 @default.
• W1995755728 hasAuthorship W1995755728A5037868315 @default.
• W1995755728 hasAuthorship W1995755728A5041806038 @default.
• W1995755728 hasAuthorship W1995755728A5049130253 @default.
• W1995755728 hasAuthorship W1995755728A5062796761 @default.
• W1995755728 hasAuthorship W1995755728A5066082558 @default.
• W1995755728 hasAuthorship W1995755728A5073359098 @default.
• W1995755728 hasConcept C126322002 @default.
• W1995755728 hasConcept C134018914 @default.
• W1995755728 hasConcept C170493617 @default.
• W1995755728 hasConcept C185592680 @default.
• W1995755728 hasConcept C2775960820 @default.
• W1995755728 hasConcept C2776572282 @default.
• W1995755728 hasConcept C2779306644 @default.
• W1995755728 hasConcept C2779679481 @default.
• W1995755728 hasConcept C2780378035 @default.
• W1995755728 hasConcept C2780675426 @default.
• W1995755728 hasConcept C2780689927 @default.
• W1995755728 hasConcept C55493867 @default.
• W1995755728 hasConcept C71924100 @default.
• W1995755728 hasConcept C86803240 @default.
• W1995755728 hasConcept C88045685 @default.
• W1995755728 hasConcept C95444343 @default.
• W1995755728 hasConceptScore W1995755728C126322002 @default.
• W1995755728 hasConceptScore W1995755728C134018914 @default.
• W1995755728 hasConceptScore W1995755728C170493617 @default.
• W1995755728 hasConceptScore W1995755728C185592680 @default.
• W1995755728 hasConceptScore W1995755728C2775960820 @default.
• W1995755728 hasConceptScore W1995755728C2776572282 @default.
• W1995755728 hasConceptScore W1995755728C2779306644 @default.
• W1995755728 hasConceptScore W1995755728C2779679481 @default.
• W1995755728 hasConceptScore W1995755728C2780378035 @default.
• W1995755728 hasConceptScore W1995755728C2780675426 @default.
• W1995755728 hasConceptScore W1995755728C2780689927 @default.

• next